Batoclimab

温馨提示：以下所有观点均是个人投资心得体会，和个人身边真实案例分享，供大家交流讨论，不涉及任何投资建议，请大家别盲目跟风，盈亏自负！成年人要有自己的判断。 经历连续两年估值消化之后，2026年创新药板块迎来三重核心催化：全球流动性预期宽松、国产创新药出海授权订单密集落地、ADC、双抗多抗新一代生物药集中进入临床III期与商业化阶段。 不少股民最近纠结科技高位回调，资金正在高低切换，低位医药创新赛道迎来资金布局窗口，尤其是下周，多家药企披露临床数据、CXO龙头发布订单公告，细分赛道分化行情会进一步放大。 很多散户看创新药只会简单划分CXO、肿瘤药，却分不清三条核心细分的内在逻辑：CXO是整个创新产业的“卖水人”，不管药企研发成功与否，都能稳定赚取研发、生产服务费；ADC是当下商业化兑现最快的肿瘤黄金赛道，多款国产新药即将获批；双抗、多抗是下一代免疫治疗核心方向，海外药企大额授权订单频发，长期成长空间广阔。 一、下周创新药集体走强，四大底层催化全部落地 很多人疑惑，为什么沉寂两年的创新药，会在近期持续回暖，下周行情值得重点跟踪，核心源于四大不可逆利好共振： 催化1：全球流动性边际宽松，创新药估值迎来修复窗口 创新药属于长久期成长资产，对海外利率变化高度敏感。2026年海外就业数据持续走弱，市场加息预期大幅降温，美元流动性宽松预期升温，港股、A股创新药板块估值迎来修复窗口期。对比美股生物科技指数，近期创出五年新高，全球创新药风险偏好同步回升，北向资金持续加仓国内医药龙头。 催化2：CXO订单全面回暖，中报业绩集体超预期 CXO作为医药研发外包服务商，是行业景气度先行指标。2026年上半年国内头部CXO企业全部上调全年业绩指引，在手订单持续创新高，ADC、双抗多抗等新型生物药外包订单增速超40%。海外药企为压缩研发成本，持续将早期研发、商业化生产订单转移至国内，内需叠加外需双向爆发，业绩确定性拉满。 催化3：国产新一代生物药进入收获期，临床、商业化双线兑现 2026年成为国产ADC、双抗药物集中兑现年份：全球首款国产双抗ADC正式获批上市，数十款ADC进入III期临床；双抗药物海外大额授权订单接连落地，单笔交易最高超60亿美元，证明国内创新药技术实力获得全球药企认可，产业从“仿创结合”正式迈入“全球原创”阶段。 催化4：资金高低切换，低位医药板块迎来增量资金流入 前期AI算力、半导体科技赛道持续高位抱团，资金获利兑现需求强烈，大量风险偏好资金转向估值处于历史低位、基本面持续改善的创新药板块。同时多家医药上市公司发布股份回购公告，产业资本底部增持，进一步夯实板块底部支撑，下周资金轮动行情有望持续发酵。 二、第一大主线：CXO四大龙头，创新药赛道“卖水人”，订单持续饱满 先简单科普CXO：分为CRO（药物研发服务）、CDMO（药物定制生产），药企研发新药，全程都需要外包给CXO企业，不管新药研发成功还是失败，企业都能收取服务费，行业业绩稳定性极强，也是布局创新药最稳妥的细分赛道。 市场公认国内四大CXO龙头，覆盖全产业链，差异化布局ADC、双抗多抗高端外包业务，2026年订单、产能同步扩张： 1、药明康德（全产业链综合CXO龙头） 核心业务：覆盖药物发现、临床CRO、小分子CDMO、生物药CDMO，国内唯一全链条CXO平台，旗下药明合联是全球最大ADC外包服务商，市场份额24%。 订单与业绩：2026年上半年营收288.97亿元，同比增长38.93%，上半年净利润首次突破百亿，大幅上调全年业绩指引；截至6月末在手订单664.30亿元，同比增长25.2%。其中ADC、双抗多抗外包管线3700余个，持续新建常州大型生产基地，产能持续扩张匹配海量订单。 核心优势：全球布局九大研发生产基地，海外客户占比超70%，承接全球头部药企创新药订单；ADC、多肽、寡核苷酸新型分子业务高速增长，是国内唯一能一站式完成双抗、ADC研发生产的企业，行业壁垒无对手。 2、泰格医药（临床CRO绝对龙头） 核心业务：专注临床阶段临床试验服务，全球前十临床CRO唯一中国企业，覆盖I-IV期全球多中心临床试验，同时布局临床前安评、生物药CDMO。 订单与业绩：国内创新药临床需求持续爆发，2026年临床订单同比增长28%，在手订单覆盖未来两年营收；国内90%以上创新药企临床项目选择泰格合作，海外跨国药企临床外包订单持续回流。 核心优势：国内临床资源壁垒最高，合作医院、临床研究者覆盖全国；双抗、ADC新药临床经验丰富，大量新一代生物药III期临床由公司承接，创新药商业化落地的核心配套服务商。 3、康龙化成（药物发现+大分子CDMO龙头） 核心业务：前端药物发现实验室服务、小分子CDMO、双抗/抗体生物药生产，海外客户占比超80%，海外创新药企核心合作方。 订单与业绩：2026上半年新签订单同比增长30%，大分子生物药（双抗、ADC中间体）订单增速超50%，海外Biotech企业研发预算提升，外包订单持续放量，新建大分子生产基地下半年投产。 核心优势：海外实验室布局完善，承接大量海外前沿双抗、多抗早期研发项目，小分子+大分子双线均衡发展，受益全球创新药研发浪潮。 4、昭衍新药（临床前安评CRO龙头） 核心业务：专注新药上市前安全性评价（安评），国内资质最全、实验动物产能最大企业，创新药上市必经环节，行业刚需赛道。 订单与业绩：实验猴供给缺口持续存在，安评订单量价齐升，2026年在手订单充足，双抗、ADC等生物药安评项目占比持续提升，新建安评基地持续释放产能。 核心优势：国内稀缺全套国际认证安评实验室，新药想要海内外同步申报，必须经过昭衍安全性检测，客户粘性极强，不受药物临床成败影响，业绩波动极小。 三、第二大主线：ADC三杰，肿瘤治疗黄金赛道，多款新药即将商业化 ADC全称抗体偶联药物，简单理解就是“精准靶向化疗药”，精准识别肿瘤细胞，降低化疗副作用，是全球肿瘤研发最热门赛道，2026年全球市场规模突破250亿美元，国内市场规模418亿元，国内三家企业管线进度、商业化能力稳居第一梯队，称为ADC三杰： 1、恒瑞医药（国内ADC管线布局最丰富企业） 核心管线：6款ADC进入临床阶段，核心产品SHR-A1811对标全球爆款Enhertu，覆盖乳腺癌、肺癌、胃癌三大高发癌种，其中三项适应症纳入突破性治疗品种，III期临床数据优异，有望2027年前陆续获批上市。 产业配套：自建完整ADC研发、中试、商业化生产平台，无需外包，生产成本可控；同时和CXO企业合作布局新一代双抗ADC，管线梯队完整，短期、长期成长逻辑兼备。 核心优势：国内肿瘤销售渠道最强，新药获批后可以快速实现商业化放量；靶点布局差异化，覆盖HER2、Claudin 18.2、c-Met等多个黄金靶点，抗耐药新一代ADC同步研发。 2、荣昌生物（国内首款国产ADC商业化企业） 核心管线：维迪西妥是国内第一款自主研发上市HER2 ADC，已经纳入医保，持续放量；新一代MSLN靶向ADC RC88进入临床II期，布局间皮素阳性卵巢癌、胰腺癌空白赛道，差异化避开HER2红海竞争。 核心优势：国内最早搭建完整ADC技术平台，偶联、连接子、毒素全部自主研发，技术壁垒深厚；商业化团队成熟，医保落地后产品营收持续稳步增长，现金流稳定反哺研发。 3、百利天恒（全球首款双抗ADC上市企业） 核心管线：2026年6月旗下伦康依隆妥单抗获批上市，是全球第一款获批的EGFR×HER3双抗ADC，用于转移性鼻咽癌，填补全球治疗空白；多款新一代双抗ADC处于临床I/II期，差异化双靶点设计解决单靶ADC耐药难题。 核心优势：独家双抗ADC技术平台，赛道无直接竞品，产品具备first-in-class全球首创属性；海外授权合作同步推进，国内外市场双线布局，打开长期成长天花板。 四、第三大主线：双抗、多抗四大天王，下一代免疫治疗核心蓝海 双抗、多抗是比单抗、ADC更前沿的免疫药物，一个药物同时识别两个及以上肿瘤靶点，解决单靶点药物耐药问题，2026年AACR大会数据显示，全球双抗临床项目数量同比翻倍，国内四家企业平台技术、管线进度行业领先，称为双抗多抗四大天王： 1、康方生物（双抗商业化领跑者） 核心管线：国内唯一两款双抗药物获批上市企业，AK104（PD-1/CTLA4双抗）拿下三项宫颈癌、胃癌适应症；AK112（PD-1/VEGF双抗）一线肺癌III期临床数据优异，即将递交上市申请；同步布局三抗、双抗ADC前沿管线。 核心优势：双抗临床数据成熟，两款产品已经商业化产生稳定营收，现金流支撑持续研发；IO2.0+ADC双线战略，双抗与ADC管线协同研发，技术平台持续迭代。 2、三生国健（多抗技术平台龙头） 核心管线：搭建完整双抗、三抗、四抗全技术平台，管线覆盖自身免疫、肿瘤两大赛道，CD3/CD19/BCMA三特异性抗体进入临床阶段，多款双抗药物进入IND申报阶段；2025年一款PD-1/VEGF双抗海外授权，总交易金额60.5亿美元，创下国产创新药出海纪录。 核心优势：深耕抗体药物研发20余年，大分子工艺成熟，多抗分子设计自主可控，海外药企大额授权验证平台技术价值，长期全球化空间广阔。 3、和铂医药（全人源双抗平台稀缺标的） 核心管线：独家Harbour Mice全人源抗体小鼠平台，产出多款全球首创双抗、重链抗体，多款产品授权阿斯利康、大冢等跨国药企，持续获取大额首付款；巴托利单抗进入上市冲刺阶段，多款双抗进入II期临床。 核心优势：全球稀缺全人源抗体技术平台，海外药企合作需求旺盛，持续稳定产生BD授权收入，无需单纯依靠新药上市盈利，业绩抗风险能力更强。 4、诺诚健华（肿瘤自免双赛道双抗布局） 核心管线：同时布局小分子、ADC、双抗多条管线，双抗聚焦肿瘤、自身免疫疾病稀缺靶点，多款双抗进入临床I/II期；已有三款创新药商业化销售，稳定现金流支撑前沿管线研发，海内外同步开展多中心临床。 核心优势：小分子+大分子协同研发，双抗药物搭配自有靶向药联合治疗，临床方案差异化优势明显，港股+A股双重上市，融资渠道充足。 五、客观理性看待赛道三大潜在风险，规避炒作陷阱 文章全程客观科普，不单方面唱多创新药赛道，梳理三大需要持续跟踪的风险，普通投资者理性区分优质龙头与题材概念股： 1. 临床研发失败风险：不管ADC还是双抗新药，临床III期存在数据不及预期、临床失败风险，管线单一企业波动会更大。优先选择管线丰富、多款产品进入临床后期、已有商业化产品的龙头，对冲单一管线研发风险。 2. 海外地缘与订单波动风险：CXO企业海外订单占比较高，若全球药企缩减研发预算，会影响订单增速；海外生物安全政策变化，短期扰动业务拓展。四大CXO龙头国内+海外订单均衡布局，抗波动能力更强。 3. 短期估值透支风险：下周板块资金集中流入，部分短期涨幅过快的标的会出现估值阶段性偏高，短期存在回调消化估值的可能，不适合短线追高博弈，适合逢调整长期跟踪产业逻辑。 同时教大家简单分辨真正创新龙头和蹭热点概念股：查看企业公告，确认是否有真实临床III期管线、商业化产品、大额海外BD授权、稳定在手订单；仅在互动平台提及布局ADC、双抗，无临床数据、无产能、无研发投入的企业，纯题材炒作，需要直接规避。 六、普通投资者理性跟踪思路，立足产业周期，拒绝短线投机 结合CXO、ADC、双抗多抗三大细分赛道景气逻辑，给普通读者三条客观观察思路，仅做产业科普，不构成任何投资指导： 1. 分赛道分层跟踪，把握产业先后顺序 短期优先跟踪CXO板块，订单、业绩数据确定性最强，是板块行情先行指标；中期关注ADC赛道，多款新药集中获批商业化，业绩弹性最大；长期布局双抗、多抗赛道，属于5-10年长周期蓝海赛道，适合长期产业观察。下周重点关注各家企业临床数据披露、订单公告两大核心信息。 2. 摒弃单边极端思维，不盲目追涨杀跌 不要因为板块连续上涨就全盘看多，忽略估值风险；也不要因为单日回调就否定创新药长期修复逻辑。本轮创新药行情核心驱动力是产业基本面改善，不是短期题材炒作，行情会伴随临床数据、订单公告持续分化，优质龙头具备持续修复空间，纯题材概念股上涨持续性弱。 3. 建立完整产业链认知，看懂上下游联动逻辑 CXO是上游配套，ADC、双抗是下游创新药企，两条赛道景气度相互传导：创新药企研发投入提升，直接带动CXO订单增长；CXO产能、技术平台完善，又加速新药研发落地。完整看懂上下游联动逻辑，才能精准把握板块轮动节奏。 看完CXO四大龙头、ADC三杰、双抗多抗四大天王完整梳理，想问问各位读者： 你平时布局医药创新赛道，更偏向业绩稳定的CXO龙头，还是弹性更大的ADC、双抗创新药企？你认为下周创新药三大细分，哪一条赛道资金关注度会更高？欢迎在评论区留下你的观点，一起理性交流产业逻辑！ 免责声明:本文仅为个人观点，不荐股，不构成任何投资建议，市场有风险，决策需谨慎！据此操作风险自负！以上纯属科普！写文章不易，不喜勿喷哦！谢谢大家

All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat rheumatoid arthritis (D2T RA), Sjögren’s disease (SjD) and cutaneous lupus erythematosus (CLE) Current cash balance provides runway to the potential launch of IMVT-1402 in GD Roivant will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026 DURHAM, N.C., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its first fiscal quarter ended June 30, 2026. Recent Highlights and Upcoming Milestones: Immunovant’s development plans for IMVT-1402 remain on track across all six announced indications. The Company expects to provide further updates on its potentially registrational IMVT-1402 D2T RA program and report topline data from the proof-of-concept trial of IMVT-1402 in CLE in the second half of calendar year 2026. In calendar year 2027, topline data are anticipated for the potentially registrational trials evaluating IMVT-1402 in GD and MG. Topline data are expected to follow in calendar year 2028 for the potentially registrational trials of IMVT-1402 in CIDP and SjD. Financial Highlights for Fiscal First Quarter Ended June 30, 2026: ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Cash Position: As of June 30, 2026, Immunovant’s cash and cash equivalents totaled $797.8 million, providing runway to the potential commercial launch of IMVT-1402 in GD, based on our current operating plan. Research and Development Expenses: Research and development (R&D) expenses were $142.6 million for the three months ended June 30, 2026, compared to $101.2 million for the three months ended June 30, 2025. The increase was primarily due to activities related to our clinical trials of IMVT-1402, including contract manufacturing costs, partially offset by lower overall costs as we wind-down our batoclimab clinical trials. Non-GAAP R&D expenses were $135.4 million for the three months ended June 30, 2026, compared to $93.3 million for the three months ended June 30, 2025. General and Administrative Expenses: General and administrative (G&A) expenses were $17.7 million for the three months ended June 30, 2026, compared to $26.0 million for the three months ended June 30, 2025. The decrease was primarily due to lower personnel-related expenses, professional fees, market research costs and information technology costs. Non-GAAP G&A expenses were $11.2 million for the three months ended June 30, 2026, compared to $15.4 million for the three months ended June 30, 2025. Net Loss: Net loss was $153.2 million ($0.75 per common share) for the three months ended June 30, 2026, compared to $120.6 million ($0.71 per common share) for the three months ended June 30, 2025. Net loss for the three months ended June 30, 2026 and June 30, 2025 included $13.8 million and $18.5 million, respectively, related to non-cash stock-based compensation expense. Non-GAAP net loss was $139.4 million for the three months ended June 30, 2026, compared to $102.1 million for the three months ended June 30, 2025. Common Stock: As of June 30, 2026, there were 206,264,878 shares of common stock issued and outstanding. Non-GAAP Financial Measures: In addition to reporting the financial results in accordance with accounting principles generally accepted in the United States of America (GAAP), Immunovant reports certain financial results that differ from what is reported under GAAP. Immunovant believes these non-GAAP financial measures are useful to investors and others because they allow for additional information with respect to financial measures used by management in its financial and operational decision-making and they may be used by institutional investors and the analyst community to help them analyze the health of Immunovant’s business. However, there are a number of limitations related to the use of non-GAAP financial measures, and these non-GAAP measures should be considered in addition to, not as a substitute for or in isolation from, Immunovant’s financial results prepared in accordance with GAAP. Other companies, including companies in Immunovant’s industry, may calculate these non-GAAP financial measures differently or not at all, which reduces their usefulness as comparative measures. About Immunovant, Inc. Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases and is a majority-owned subsidiary of Roivant (Nasdaq: ROIV). As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com. Investor Conference Call Information Roivant will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026. To access the conference call by phone, please register online using this Registrational link . The presentation and webcast details will also be available under “Events & Presentations” in the Investors section of the Immunovant website at The archived webcast will be available on Immunovant’s website after the conference call. Forward-Looking Statements This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “can,” “may,” “might,” “will,” “would,” “should,” “expect,” “believe,” “estimate,” “design,” “plan,” “intend,” and other similar expressions are intended to identify forward-looking statements. Such forward looking statements include statements regarding Immunovant’s progress towards developing IMVT-1402 across a broad range of indications; Immunovant’s expectations regarding the availability of results of clinical trials of IMVT-1402 and whether those results may be adequate to support registration; and the Company’s beliefs regarding the potential sufficiency of its cash runway. All forward-looking statements are based on estimates and assumptions by Immunovant’s management that, although Immunovant believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Immunovant expected. Such risks and uncertainties include, among others: Immunovant may not be able to protect or enforce its intellectual property rights; initial results or other preliminary analyses or results of early clinical trials may not be predictive final trial results or of the results of later clinical trials; the timing and availability of data from clinical trials; the timing of discussions with regulatory agencies, as well as regulatory submissions and potential approvals; the continued development of Immunovant’s product candidates, including the number and timing of the commencement of additional clinical trials; Immunovant’s scientific approach, clinical trial design, indication selection, regulatory strategy, and general development progress; future clinical trials may not confirm any safety, potency, or other product characteristics described or assumed in this press release; any product candidate that Immunovant develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; Immunovant’s product candidates may not be beneficial to patients, or even if approved by regulatory authorities, successfully commercialized; the potential impact of global factors, such as international trade tariffs, geopolitical tensions, and adverse macroeconomic conditions on Immunovant’s business operations and supply chain, including its clinical development plans and timelines; Immunovant’s business is heavily dependent on the successful development, regulatory approval, and commercialization of IMVT-1402; Immunovant is at various stages of clinical development for IMVT-1402; and Immunovant will require additional capital to fund its operations and advance IMVT-1402 through clinical development. These and other risks and uncertainties are more fully described in Immunovant’s periodic and other reports filed with the Securities and Exchange Commission (SEC), including in the section titled “Risk Factors” in Immunovant’s Annual Report on Form 10-K filed with the SEC on May 20, 2026, and Immunovant’s subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Immunovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. IMMUNOVANT, INC. Condensed Consolidated Statements of Operations (Unaudited, in thousands, except share and per share data) Three Months Ended June 30, 2026 2025 Operating expenses: Research and development $ 142,631 $ 101,200 General and administrative 17,692 26,024 Total operating expenses 160,323 127,224 Interest income, net (7,095 ) (6,337 ) Other income, net (4 ) (1,187 ) Loss before provision for income taxes (153,224 ) (119,700 ) Provision for income taxes — 913 Net loss $ (153,224 ) $ (120,613 ) Net loss per common share – basic and diluted $ (0.75 ) $ (0.71 ) Weighted-average common shares outstanding – basic and diluted 205,545,373 170,872,994 IMMUNOVANT, INC. Condensed Consolidated Balance Sheets (Unaudited, in thousands, except share and per share data) June 30, 2026 March 31, 2026 Assets Current assets: Cash and cash equivalents $ 797,798 $ 902,110 Accounts receivable 697 1,133 Prepaid expenses and other current assets 52,683 45,576 Total current assets 851,178 948,819 Property and equipment, net 351 443 Other assets 961 7,752 Total assets $ 852,490 $ 957,014 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 10,138 $ 7,541 Accrued expenses and other current liabilities 106,964 96,881 Total current liabilities 117,102 104,422 Total liabilities 117,102 104,422 Commitments and contingencies Stockholders’ equity: Series A preferred stock, par value $0.0001 per share, 10,000 shares authorized, issued and outstanding at June 30, 2026 and March 31, 2026 — — Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at June 30, 2026 and March 31, 2026 — — Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 206,264,878 shares issued and outstanding at June 30, 2026 and 500,000,000 shares authorized, 203,940,353 shares issued and outstanding at March 31, 2026 20 20 Additional paid-in capital 2,632,996 2,596,971 Accumulated other comprehensive income 725 730 Accumulated deficit (1,898,353 ) (1,745,129 ) Total stockholders’ equity 735,388 852,592 Total liabilities and stockholders’ equity $ 852,490 $ 957,014 IMMUNOVANT, INC. Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited, in thousands) Three months ended June 30, Note 2026 2025 Net loss: $ (153,224 ) $ (120,613 ) Adjustments Research and development: Stock-based compensation (1 ) 7,254 7,865 General and administrative: Stock-based compensation (1 ) 6,520 10,645 Estimated income tax impact from adjustments — 42 Adjusted net loss (Non-GAAP) $ (139,450 ) $ (102,061 ) Three months ended June 30, Note 2026 2025 Research and Development Expenses $ 142,631 $ 101,200 Adjustments: Stock-based compensation (1 ) 7,254 7,865 Adjusted research and development expenses (Non-GAAP) $ 135,377 $ 93,335 Three months ended June 30, Note 2026 2025 General and Administrative Expenses $ 17,692 $ 26,024 Adjustments: Stock-based compensation (1 ) 6,520 10,645 Adjusted general and administrative expenses (Non-GAAP) $ 11,172 $ 15,379 (1) Represents non-cash stock-based compensation expense Contacts: Investors Keyur Parekh keyur.parekh@roivant.com Media Stephanie Lee stephanie.lee@roivant.com